166
Participants
Start Date
June 12, 2017
Primary Completion Date
March 10, 2020
Study Completion Date
January 17, 2022
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0018, Hong Kong
Local Institution - 0022, Randwick
Local Institution - 0034, Parkville
Local Institution, Clayton
Local Institution - 0035, Sth Brisbane
Local Institution - 0033, Nedlands
Local Institution - 0004, New York
Local Institution - 0017, New York
Local Institution - 0066, Philadelphia
Local Institution - 0061, Hamburg
Local Institution - 0005, Baltimore
Local Institution - 0038, Madrid
Local Institution, Charleston
Local Institution - 0046, Gainesville
Local Institution - 0029, Bordeaux
Local Institution - 0012, Memphis
Local Institution - 0060, Essen
Cincinnati Children'S Hospital Medical Center, Cincinnati
Local Institution - 0036, Valencia
Local Institution - 0028, Angers
Local Institution - 0064, Vandœuvre-lès-Nancy
Local Institution - 0027, Lille
Local Institution - 0044, St Louis
Local Institution - 0025, Lyon
Local Institution - 0063, Heidelberg
Local Institution - 0042, Houston
Local Institution - 0016, Aurora
Local Institution - 0057, Los Angeles
Local Institution - 0062, Würzburg
Local Institution - 0048, Moscow
Local Institution - 0059, Haifa
Local Institution - 0058, Ramat Gan
Local Institution - 0011, Chicago
Local Institution - 0043, Boston
Local Institution - 0052, Porto Alegre
Local Institution - 0051, Barretos
Local Institution - 0053, Ribeirão Preto
Local Institution - 0049, São Paulo
Local Institution - 0050, São Paulo
Local Institution - 0021, Toronto
Local Institution - 0001, Montreal
Local Institution - 0002, Québec
Local Institution - 0024, Marseille
Local Institution - 0023, Paris
Local Institution - 0026, VIillejuif
Local Institution - 0007, Rotterdam
Local Institution - 0008, Utrecht
Local Institution - 0067, Oslo
Local Institution - 0047, Warsaw
Local Institution - 0037, Esplugues de Llobregat
Local Institution - 0065, Solna
Local Institution - 0010, London
Local Institution - 0013, Liverpool
Local Institution - 0015, Newcastle upon Tyne
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY